Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel Free ATXI Stock Alerts

Avenue Therapeutics (ATXI) Competitors

Avenue Therapeutics logo
$0.24 0.00 (0.00%)
As of 05/22/2026 03:20 PM Eastern
Compare

ATXI vs. SXTP, PPBT, IOBT, SHPH, and VIVS

Should you buy Avenue Therapeutics stock or one of its competitors? MarketBeat compares Avenue Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avenue Therapeutics include 60 Degrees Pharmaceuticals (SXTP), Purple Biotech (PPBT), IO Biotech (IOBT), Shuttle Pharmaceuticals (SHPH), and VivoSim Labs (VIVS). These companies are all part of the "pharmaceutical products" industry.

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals had 7 more articles in the media than Avenue Therapeutics. MarketBeat recorded 7 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 beat 60 Degrees Pharmaceuticals' score of -0.80 indicating that Avenue Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Negative
Avenue Therapeutics Neutral

60 Degrees Pharmaceuticals has a beta of 2.69, meaning that its stock price is 169% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market.

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, indicating a potential upside of 835.81%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Avenue Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
60 Degrees Pharmaceuticals-574.91% N/A -131.48%
Avenue Therapeutics N/A -471.57%-296.50%

60 Degrees Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.41M2.79-$7.36M-$8.92N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A

Summary

60 Degrees Pharmaceuticals beats Avenue Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Avenue Therapeutics compare to Purple Biotech?

Avenue Therapeutics (NASDAQ:ATXI) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 941.67%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Purple Biotech
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Purple Biotech had 9 more articles in the media than Avenue Therapeutics. MarketBeat recorded 9 mentions for Purple Biotech and 0 mentions for Avenue Therapeutics. Purple Biotech's average media sentiment score of 0.80 beat Avenue Therapeutics' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Avenue Therapeutics Neutral
Purple Biotech Positive

Avenue Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Purple Biotech's return on equity of -123.63% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Purple Biotech N/A -123.63%-98.72%

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A
Purple BiotechN/AN/A-$26.39M-$18.84N/A

Summary

Purple Biotech beats Avenue Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to IO Biotech?

Avenue Therapeutics (NASDAQ:ATXI) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled IO Biotech'saverage media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
IO Biotech Neutral

IO Biotech has a consensus target price of $3.50, indicating a potential upside of 7,191.67%. Given IO Biotech's stronger consensus rating and higher probable upside, analysts clearly believe IO Biotech is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
IO Biotech
2 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.60

Avenue Therapeutics' return on equity of -471.57% beat IO Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
IO Biotech N/A -517.22%-200.69%

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 54.8% of IO Biotech shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 2.3% of IO Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A
IO BiotechN/AN/A-$95.49M-$1.35N/A

Avenue Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the broader market. Comparatively, IO Biotech has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Summary

Avenue Therapeutics and IO Biotech tied by winning 5 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to Shuttle Pharmaceuticals?

Avenue Therapeutics (NASDAQ:ATXI) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Shuttle Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Shuttle Pharmaceuticals and 0 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 equaled Shuttle Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
Shuttle Pharmaceuticals Neutral

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Shuttle Pharmaceuticals' return on equity of -408.34% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Shuttle Pharmaceuticals N/A -408.34%-138.15%

Avenue Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A
Shuttle PharmaceuticalsN/AN/A-$11.72M-$4.77N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Shuttle Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Shuttle Pharmaceuticals beats Avenue Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to VivoSim Labs?

Avenue Therapeutics (NASDAQ:ATXI) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Avenue Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
VivoSim Labs -861.27%-15.51%-11.31%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
VivoSim Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Avenue Therapeutics has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled VivoSim Labs'average media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
VivoSim Labs Neutral

VivoSim Labs has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.53N/A
VivoSim Labs$140K25.35-$2.48M-$3.15N/A

Summary

VivoSim Labs beats Avenue Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATXI vs. The Competition

Export
MetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$794K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio0.011.4621.0025.66
Price / SalesN/A119.63562.1886.31
Price / CashN/A20.0743.4956.67
Price / Book0.137.5910.417.14
Net Income-$10.38M-$3.64M$3.57B$335.98M
7 Day Performance-13.96%3.01%6.40%4.11%
1 Month Performance-63.50%76.62%3.54%2.52%
1 Year Performance15.37%126.61%34.14%35.04%

Avenue Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATXI
Avenue Therapeutics
N/A$0.24
flat		N/A+15.4%$794KN/A0.014
SXTP
60 Degrees Pharmaceuticals
2.7221 of 5 stars		$1.38
-1.4%		$14.10
+921.0%		-81.6%$3.68M$1.41MN/A3
PPBT
Purple Biotech
3.4614 of 5 stars		$2.65
-11.0%		$30.00
+1,031.6%		-88.0%$3.50MN/AN/A20
IOBT
IO Biotech
N/A$0.05
flat		$3.50
+7,191.7%		N/A$3.45MN/AN/A30
SHPH
Shuttle Pharmaceuticals
0.2861 of 5 stars		$0.57
-3.4%		N/A-86.6%$3.35MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel